|
1
|
Howlader N, Noone AM, Krapcho M, Garshell
J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,
et al: SEER Cancer Statistics Review, 1975–2011. National Cancer
Institute. Surveillance, Epidemiology, and End Results Program.
National Institutes of Health (Bethesda, MD, USA). 2013.http://seer.cancer.gov/csr/1975_2012Accessed.
February. 2016
|
|
2
|
American Cancer Society. Cancer
Infographics Gallery (Atlanta, GA, USA). 2015.https://.cancer.org/infographicsAccessed. March.
2016
|
|
3
|
Inklekofer AM and Younes A: Precision
therapy for lymphoma - current state and future directions. Nat Rev
Clin Oncol. 11:585–596. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Diaz T, Navarro A, Ferrer G, Gel B, Gaya
A, Artells R, Bellosillo B, Garcia-Garcia M, Serrano S, Martínez A
and Monzo M: Lestaurtinib inhibition of the Jak/STAT signaling
pathway in hodgkin lymphoma inhibits proliferation and induces
apoptosis. PLoS One. 6:e188562011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hart S, Goh KC, Novotny-Diermayr V, Hu CY,
Hentze H, Tan YC, Madan B, Amalini C, Loh YK, Ong LC, et al:
SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the
treatment of myeloid and lymphoid malignancies. Leukemia.
25:1751–1759. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Burington B, Yue P, Shi X, Advani R, Lau
JT, Tan J, Stinson S, Stinson J, Januario T, de Vos S, et al: CD40
pathway activation status predicts response to CD40 therapy in
diffuse large B cell lymphoma. Sci Transl Med. 3:74ra222011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Arrondeau J, Gan HK, Razak AR, Paoletti X
and Le Tourneau C: Development of anti-cancer drugs. Discov Med.
10:355–362. 2010.PubMed/NCBI
|
|
8
|
Masood A, Sher T, Paulus A, Miller KC,
Chitta KS and Chanan-Khan A: Targeted treatment for chronic
lymphocytic leukemia. Onco Targets Ther. 4:169–183. 2011.PubMed/NCBI
|
|
9
|
Pedroza DA, De Leon F, Varela-Ramirez A,
Lema C, Aguilera RJ and Mito S: The cytotoxic effect of
2-acylated-1,4-naphthohydroquinones on leukemia/lymphoma cells.
Bioorg Med Chem. 22:842–847. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Martínez A, Carreon T, Iniguez E,
Anzellotti A, Sánchez A, Tyan M, Sattler A, Herrera L, Maldonado RA
and Sánchez-Delgado RA: Searching for new chemotherapies for
tropical diseases: Ruthenium-clotrimazole complexes display high in
vitro activity against Leishmania major and Trypanosoma
cruzi and low toxicity toward normal mammalian cells. J Med
Chem. 55:3867–3877. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Robles-Escajeda E, Lerma D, Nyakeriga AM,
Ross JA, Kirken RA, Aguilera RJ and Varela-Ramirez A: Searching in
mother nature for anti-cancer activity: Anti-proliferative and
pro-apoptotic effect elicited by green barley on leukemia/lymphoma
cells. PLoS One. 8:e735082013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Martínez A, Rajapakse CS, Sánchez-Delgado
RA, Varela-Ramirez A, Lema C and Aguilera RJ:
Arene-Ru(II)-chloroquine complexes interact with DNA, induce
apoptosis on human lymphoid cell lines and display low toxicity to
normal mammalian cells. J Inorg Biochem. 104:967–977. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Robles-Escajeda E, Martínez A,
Varela-Ramirez A, Sánchez-Delgado RA and Aguilera RJ: Analysis of
the cytotoxic effects of ruthenium-ketoconazole and
ruthenium-clotrimazole complexes on cancer cells. Cell Biol
Toxicol. 29:431–443. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Elie BT, Levine C, Ubarretxena-Belandia I,
Varela-Ramírez A, Aguilera RJ, Ovalle R and Contel M: Water soluble
phosphane-gold(I) complexes. Applications as recyclable catalysts
in a three-component coupling reaction and as antimicrobial and
anticancer agents. Eur J Inorg Chem. 2009:3421–3430. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shaik N, Martínez A, Augustin I,
Giovinazzo H, Varela-Ramírez A, Sanaú M, Aguilera RJ and Contel M:
Synthesis of apoptosis-inducing iminophosphorane organogold(III)
complexes and study of their interactions with biomolecular
targets. Inorg Chem. 48:1577–1587. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Santiago-Vazquez Y, Das S, Das U,
Robles-Escajeda E, Ortega NM, Lema C, Varela-Ramírez A, Aguilera
RJ, Balzarini J, De Clercq E, et al: Novel
3,5-bis(arylidene)-4-oxo-1-piperidinyl dimers: Structure-activity
relationships and potent antileukemic and antilymphoma
cytotoxicity. Eur J Med Chem. 77:315–322. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pati HN, Das U, Sharma RK and Dimmock JR:
Cytotoxic thiol alkylators. Mini Rev Med Chem. 7:131–139. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen EX and Moore MJ: Principles of
Medical Pharmacology. Kalant H, Grant DM and Mitchell J: (7th).
Saunders-Elsevier. (Toronto, Canada). 7782007.
|
|
19
|
Das U, Sharma RK and Dimmock JR:
1,5-diaryl-3-oxo-1,4- pentadienes: A case for antineoplastics with
multiple targets. Curr Med Chem. 16:2001–2020. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Das U, Pati HN, Sakagami H, Hashimoto K,
Kawase M, Balzarini J, De Clercq E and Dimmock JR:
3,5-Bis(benzylidene)-1-[3-(2-
hydroxyethylthio)propanoyl]piperidin-4-ones: A novel cluster of
potent tumor-selective cytotoxins. J Med Chem. 54:3445–3449. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pandeya SN and Dimmock JR: Chemical
parameters in drug design. An Introduction to Drug Design. New Age
International. (New Delhi, India). 901997.
|
|
22
|
Hossain M, Das U, Umemura N, Sakagami H,
Balzarini J, De Clercq E, Kawase M and Dimmock JR: Tumour-specific
cytotoxicity and structure-activity relationships of novel
1-[3-(2-methoxyethylthio)propionyl]-3,5-bis(benzylidene)-4-pip
eridones. Bioorg Med Chem (In press).
|
|
23
|
Schneider U, Schwenk HU and Bornkamm G:
Characterization of EBV-genome negative ‘null’ and ‘T’ cell lines
derived from children with acute lymphoblastic leukemia and
leukemic transformed non-Hodgkin lymphoma. Int J Cancer.
19:621–626. 1977. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hurwitz R, Hozier J, LeBien T, Minowada J,
Gajl-Peczalska K, Kubonishi I and Kersey J: Characterization of a
leukemic cell line of the pre-B phenotype. Int J Cancer.
23:174–180. 1979. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Foley GE, Lazarus H, Farber S, Uzman BG,
Boone BA and McCarthy RE: Continuous culture of human lymphoblasts
from peripheral blood of a child with acute leukemia. Cancer.
18:522–529. 1965. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nunes LM, Robles-Escajeda E,
Santiago-Vazquez Y, Ortega NM, Lema C, Muro A, Almodovar G, Das U,
Das S, Dimmock JR, et al: The gender of cell lines matters when
screening for novel anti-cancer drugs. AAPS J. 16:872–874. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lema C, Varela-Ramirez A and Aguilera RJ:
Differential nuclear staining assay for high-throughput screening
to identify cytotoxic compounds. Curr Cell Biochem. 1:1–14.
2011.PubMed/NCBI
|
|
28
|
Robles-Escajeda E, Das U, Ortega NM, Parra
K, Francia G, Dimmock JR, Varela-Ramirez A and Aguilera RJ: A novel
curcumin-like dienone induces apoptosis in triple-negative breast
cancer cells. Cell Oncol. Feb 26–2016.(Epub ahead of print).
View Article : Google Scholar
|
|
29
|
Varela-Ramirez A, Costanzo M, Carrasco YP,
Pannell KH and Aguilera RJ: Cytotoxic effects of two organotin
compounds and their mode of inflicting cell death on four mammalian
cancer cells. Cell Biol Toxicol. 27:159–168. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fadok VA, de Cathelineau A, Daleke DL,
Henson PM and Bratton DL: Loss of phospholipid asymmetry and
surface exposure of phosphatidylserine is required for phagocytosis
of apoptotic cells by macrophages and fibroblasts. J Biol Chem.
276:1071–1077. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Williamson P and Schlegel RA: Back and
forth: The regulation and function of transbilayer phospholipid
movement in eukaryotic cells. Mol Membr Biol. 11:199–216. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Soares MM, King SW and Thorpe PE:
Targeting inside-out phosphatidylserine as a therapeutic strategy
for viral diseases. Nat Med. 14:1357–1362. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Boersma HH, Kietselaer BL, Stolk LM,
Bennaghmouch A, Hofstra L, Narula J, Heidendal GA and
Reutelingsperger CP: Past, present, and future of annexin A5: From
protein discovery to clinical applications. J Nucl Med.
46:2035–2050. 2005.PubMed/NCBI
|
|
34
|
Fadok VA, Voelker DR, Campbell PA, Cohen
JJ, Bratton DL and Henson PM: Exposure of phosphatidylserine on the
surface of apoptotic lymphocytes triggers specific recognition and
removal by macrophages. J Immunol. 148:2207–2216. 1992.PubMed/NCBI
|
|
35
|
Lavrik I, Golks A and Krammer PH: Death
receptor signaling. J Cell Sci. 118:265–267. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Danial NN and Korsmeyer SJ: Cell death:
Critical control points. Cell. 116:205–219. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Saelens X, Festjens N, Vande Walle L, van
Gurp M, van Loo G and Vandenabeele P: Toxic proteins released from
mitochondria in cell death. Oncogene. 23:2861–2874. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Tang L, Boise LH, Dent P and Grant S:
Potentiation of 1-beta-D-arabinofuranosylcytosine-mediated
mitochondrial damage and apoptosis in human leukemia cells (U937)
overexpressing bcl-2 by the kinase inhibitor 7-hydroxystaurosporine
(UCN-01). Biochem Pharmacol. 60:1445–1456. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Petit PX, Lecoeur H, Zorn E, Dauguet C,
Mignotte B and Gougeon ML: Alterations in mitochondrial structure
and function are early events of dexamethasone-induced thymocyte
apoptosis. J Cell Biol. 130:157–167. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Degterev A, Boyce M and Yuan J: A decade
of caspases. Oncogene. 22:8543–8567. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Solary E, Droin N, Bettaieb A, Corcos L,
Dimanche-Boitrel MT and Garrido C: Positive and negative regulation
of apoptotic pathways by cytotoxic agents in hematological
malignancies. Leukemia. 14:1833–1849. 2000. View Article : Google Scholar : PubMed/NCBI
|
